Stock 002004 HUAPONT LIFE SCIENCES CO.,LTD
Add to a list
To use this feature you must be a member
Log inSign up

Financials Huapont Life Sciences Co.,Ltd

Equities

002004

CNE000001JJ6

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-06-05 pm EDT 		5-day change 1st Jan Change
4.26 CNY -2.29% Intraday chart for Huapont Life Sciences Co.,Ltd -8.19% -8.58%
May. 28 Huapont Life Sciences Co.,Ltd Implements Final Cash Dividend for 2023, Payable on June 03, 2024 CI
May. 24 Huapont Life Sciences Co.,Ltd Approves Cash Dividend for 2023 CI

Valuation

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization 1 9,229 9,781 10,969 14,335 10,098 9,226
Enterprise Value (EV) 1 13,792 14,713 14,981 17,280 12,453 12,242
P/E ratio 18.4 x 15.9 x 16.8 x 21.3 x 23.3 x 30.5 x
Yield 4.77% 4.45% 3.97% 3.04% 4.31% 4.72%
Capitalization / Revenue 0.87 x 0.97 x 1.01 x 1.16 x 0.76 x 0.8 x
EV / Revenue 1.3 x 1.46 x 1.38 x 1.4 x 0.94 x 1.06 x
EV / EBITDA 6.99 x 6.96 x 6.91 x 7.87 x 4.72 x 5.67 x
EV / FCF 37 x -213 x 16.7 x 140 x 9.65 x 26 x
FCF Yield 2.7% -0.47% 5.98% 0.72% 10.4% 3.85%
Price to Book 1.02 x 1.05 x 1.14 x 1.42 x 0.99 x 0.91 x
Nbr of stocks (in thousands) 2,001,961 1,979,919 1,979,919 1,979,919 1,979,919 1,979,919
Reference price 2 4.610 4.940 5.540 7.240 5.100 4.660
Announcement Date 4/10/19 4/14/20 3/31/21 3/18/22 4/26/23 4/26/24
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales 1 10,574 10,091 10,876 12,359 13,232 11,595
EBITDA 1 1,974 2,114 2,168 2,194 2,638 2,158
EBIT 1 1,393 1,513 1,478 1,486 1,875 1,307
Operating Margin 13.17% 14.99% 13.59% 12.02% 14.17% 11.27%
Earnings before Tax (EBT) 1 1,074 1,149 1,165 1,286 1,623 892.4
Net income 1 511.3 620.2 651.7 670 433.3 302.1
Net margin 4.84% 6.15% 5.99% 5.42% 3.27% 2.61%
EPS 2 0.2500 0.3100 0.3300 0.3400 0.2188 0.1526
Free Cash Flow 1 372.9 -69.2 895.3 123.7 1,290 471.3
FCF margin 3.53% -0.69% 8.23% 1% 9.75% 4.06%
FCF Conversion (EBITDA) 18.89% - 41.29% 5.64% 48.91% 21.84%
FCF Conversion (Net income) 72.93% - 137.37% 18.46% 297.81% 155.98%
Dividend per Share 2 0.2200 0.2200 0.2200 0.2200 0.2200 0.2200
Announcement Date 4/10/19 4/14/20 3/31/21 3/18/22 4/26/23 4/26/24
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt 1 4,563 4,932 4,013 2,946 2,355 3,016
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) 2.312 x 2.333 x 1.851 x 1.342 x 0.8928 x 1.397 x
Free Cash Flow 1 373 -69.2 895 124 1,290 471
ROE (net income / shareholders' equity) 6.27% 7.15% 6.54% 6.17% 6.96% 4.09%
ROA (Net income/ Total Assets) 3.11% 3.54% 3.37% 3.19% 3.9% 2.69%
Assets 1 16,455 17,503 19,350 21,032 11,101 11,239
Book Value Per Share 2 4.530 4.720 4.860 5.110 5.150 5.100
Cash Flow per Share 2 2.170 1.700 2.080 2.220 2.110 1.910
Capex 1 1,099 1,433 1,231 1,256 1,131 1,284
Capex / Sales 10.4% 14.21% 11.32% 10.17% 8.55% 11.08%
Announcement Date 4/10/19 4/14/20 3/31/21 3/18/22 4/26/23 4/26/24
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
HUAPONT LIFE SCIENCES CO.,LTD Stock Huapont Life Sciences Co.,Ltd
-8.58% 1.19B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+43.64% 749B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+39.42% 605B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.58% 351B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.72% 328B
ABBVIE INC. Stock AbbVie Inc.
+8.78% 292B
NOVARTIS AG Stock Novartis AG
+11.92% 216B
ROCHE HOLDING AG Stock Roche Holding AG
-2.62% 214B
PFIZER, INC. Stock Pfizer, Inc.
+0.03% 167B
AMGEN INC. Stock Amgen Inc.
+6.13% 165B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 002004 Stock
  4. Financials Huapont Life Sciences Co.,Ltd